The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
BACKGROUND: Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia. METHODS: In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270, and 450. The two primary end points were the percent change from baseline in the LDL cholesterol level on day 510 and the time-adjusted percent change from baseline in the LDL cholesterol level between day 90 and day 540. RESULTS: The median age of the patients was 56 years, and 47% were men; the mean baseline level of LDL cholesterol was 153 mg per deciliter. At day 510, the percent change in the LDL cholesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisiran group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 percentage points (95% CI, -53.5 to -42.3; P<0.001). The time-averaged percent change in the LDL cholesterol level between day 90 and day 540 was a reduction of 38.1% (95% CI, -41.1 to -35.1) in the inclisiran group and an increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; P<0.001). There were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS: Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran lowered LDL-C by 47.9% in the 482 HeFH patients enrolled in ORION-9 at Day 510 [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study by Raal et al. focused on HeFH patients displayed an outlier position in the lower left quadrant of the funnel because it had both a small effect size and a wide standard error [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results were confirmed in the phase 3 ORION-9 trial which showed a − 48% LDL-C reduction of inclisiran relative to placebo among 482 patients with HeFH [138].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides and lipoprotein(a) in addition to LDL-C which makes it beneficial for complete lipid management [39, 43, 49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Cited by
Sorted by citations
Items 301–400 of 820
Gouni‐Berthold, I., Schwarz, J., & Berthold, H. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01053-3 · Cited by 16
Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
Jalink, E. A., Schonk, A. W., Boon, R. A., & Juni, R. P. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1300375 · Cited by 16
Targeting noncoding RNAs to treat atherosclerosis
Sopić, M., Vladimirov, S. S., Munjas, J., Mitić, T., Hall, I. F., Jusić, A., Ružić, D., Devaux, Y., & (https://atheronet.eu/), A. C. A. C. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16412 · Cited by 17
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Past, Present, and Future of Familial Hypercholesterolemia Management
Rocha, V. Z., & Santos, R. D. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.887 · Cited by 18
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Oral PCSK9 Inhibitors: Will They Work?
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01299-7 · Cited by 15
Recent advances in research and care of familial hypercholesterolaemia
Santos, R. D., Gidding, S. S., Bourbon, M., Iatan, I., Harada‐Shiba, M., Raal, F. J., Vallejo‐Vaz, A. J., Wiegman, A., & Watts, G. F. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00286-4 · Cited by 20
Self-citationEfficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Moustafa, B., & Testai, F. D. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106057 · Cited by 15
Approach to patients with elevated low-density lipoprotein cholesterol levels
Feingold, K. R., & Chait, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101658 · Cited by 18
How ANGPTL3 Inhibition Will Help Our Clinical Practice?
Bini, S., Tramontano, D., Minicocci, I., Costanzo, A. D., Tambaro, F., D’Erasmo, L., & Arca, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01076-w · Cited by 15
Fopase, R., Panda, C., Rajendran, A. P., Uludağ, H., & Pandey, L. M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1112755 · Cited by 16
Familial Hypercholesterolemia: Challenges for a High-Risk Population
Choi, D., Malick, W. A., Köenig, W., Rader, D. J., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.038 · Cited by 15
State of Gene Therapy for Monogenic Cardiovascular Diseases
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.11.003 · Cited by 16
Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells—Function and Therapeutic Potential
Binder, A. K., Bremm, F., Dörrie, J., & Schaft, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137275 · Cited by 16
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 15
RNA-targeted therapeutics in cardiovascular disease: the time is now
Krychtiuk, K. A., Rader, D. J., & Granger, C. B. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac052 · Cited by 15
Novel RNA-Based Therapies in the Management of Dyslipidemias
Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., & Rallidis, L. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031026 · Cited by 19
Considerations for treatment of lipid disorders during pregnancy and breastfeeding
Kaur, G., & Gulati, M. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.001 · Cited by 14
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
Alannan, M., Seidah, N. G., & Merched, A. J. (2022) · Cells · doi:10.3390/cells11244132 · Cited by 17
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
Lucà, F., Oliva, F. G., Rao, C. M., Abrignani, M. G., Amico, A. F., Fusco, S. A. D., Caretta, G., Matteo, I. D., Nora, C. D., Pilleri, A., et al. (2023) · Metabolites · doi:10.3390/metabo13080916 · Cited by 17
Csiszár, A., Tarantini, S., Yabluchanskiy, A., & Ungvari, Z. I. (2023) · GeroScience · doi:10.1007/s11357-023-01003-0 · Cited by 14
Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 17
Strategies for chronic coronary disease: A brief guide for clinicians
Krittanawong, C., Khawaja, M., Virk, H. U. H., Escobar, J., Khalid, U., Birnbaum, Y., Lavie, C. J., Sharma, S. K., Jneid, H. M., Rao, S. V., et al. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00006-w · Cited by 17
Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis
Bartneck, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.009 · Cited by 14
Evinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
Inclisiran: A Novel Small Interfering RNA Drug for Low‐Density Lipoprotein Reduction
Smith, K. W., & White, C. M. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2045 · Cited by 14
Carbohydrate and Lipid Metabolism Research Unit, F. O. H. S., Raal, F., Ableson, M., Vergelegen Mediclinic, S. W., Blignaut, S., Paarl Research Centre, P., Burgess, L., Tread Research, C. U., Coetzer, S., Accelerated Enrollment Solutions, H. C. R. C., et al. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i6.16253 · Cited by 14
Self-citationTomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
Familial hypercholesterolemia – treatment update in children, systematic review
Ziółkowska, S., Kijek, N., Zendran, I., Szuster, E., & Barg, E. (2022) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2022.116112 · Cited by 15
Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
Poznyak, A. V., Litvinova, L. S., Poggio, P., Orekhov, A. N., & Melnichenko, A. А. (2022) · Biomedicines · doi:10.3390/biomedicines10102639 · Cited by 14
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13
van den Bosch, S. E., Corpeleijn, W. E., Hutten, B. A., & Wiegman, A. (2023) · Genes · doi:10.3390/genes14030669 · Cited by 17
Lipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 14
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 13
Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis
Moustafa, B., Oparowski, D., Testai, S., Guman, I., & Trifan, G. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107633 · Cited by 16
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions
Mitsis, A., Myrianthefs, M. M., Sokratous, S., Karmioti, G., Kyriakou, M., Drakomathioulakis, M., Tzikas, S., Kadoglou, N. P. E., Karagiannidis, E., Nasoufidou, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081670 · Cited by 15
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
Averna, M. R., & Catapano, A. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.017 · Cited by 13
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Butt, W. Z., & Yee, J. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01013-x · Cited by 13
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent
Giordano, S. A., Polimeni, A., Esposito, G., Indolfi, C., & Spaccarotella, C. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000877 · Cited by 13
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Rakipovski, G., Hovingh, G. K., & Nyberg, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000718 · Cited by 14
Yamasaki, T., Horie, T., Koyama, S., Nakao, T., Baba, O., Kimura, M., Sowa, N., Sakamoto, K., Yamazaki, K., Obika, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16017-5 · Cited by 13
He, Z., Luo, Y., Yang, S., Shi, H., Huang, Y., Zhou, Z., Liu, S., Zeng, W., Liu, W.-C., Li, Y., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c18044 · Cited by 13
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Dutta, S., Shah, R., Singhal, S., Singh, S., Piparva, K. G., & Katoch, C. D. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2293201 · Cited by 12
Functions and applications of RNA interference and small regulatory RNAs
Feng, X., & Guang, S. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024196 · Cited by 14
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
Jiang, Y., Wang, Y., Ma, S., Qian, L., Jing, Y., Chen, X., & Yang, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1415668 · Cited by 16
PCSK9 Regulates Cardiac Mitochondrial Cholesterol by Promoting TSPO Degradation
Laudette, M., Lindbom, M., Cinato, M., Bergh, P., Skålén, K., Arif, M., Miljanovic, A., Czuba, T., Perkins, R., Smith, J. G., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325629 · Cited by 12
Jia, X., Rifai, M. A., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00856-6 · Cited by 12
Novel therapies for familial hypercholesterolemia
Mohamed, F., Seedat, F., & Raal, F. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000590 · Cited by 13
Self-citationTargeting NF-κB with Nanotherapy in a Mouse Model of Adult T-Cell Leukemia/Lymphoma
Rauch, D. A., Harding, J., Ratner, L., Wickline, S. A., & Pan, H. (2021) · Nanomaterials · doi:10.3390/nano11061582 · Cited by 12
PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
Stoll, F., Eidam, A., Michael, L., Bauer, J. M., & Haefeli, W. E. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00928-z · Cited by 13
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Rikhi, R. R., & Shapiro, M. D. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.14 · Cited by 13
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2277330 · Cited by 14
Agboola, F., Lin, G. A., Kazi, D. S., McKenna, A., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.961 · Cited by 12
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Li, J., Lei, X., Li, Z., & Yang, X. (2023) · Medicine · doi:10.1097/md.0000000000032728 · Cited by 12
Cordero, A., Santos‐Gallego, C. G., Manzanas, A. O., Rodríguez‐Mañero, M., Fernández-Olmo, R., & Quesada, A. J. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.16 · Cited by 11
2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.213 · Cited by 12
Giglio, R. V., Muzurović, E. M., Patti, A. M., Toth, P. P., Agarwal, M. A., Almahmeed, W. A., Klisic, A. N., Ciaccio, M., & Rizzo, M. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231186855 · Cited by 11
Li, Q., Yin, K., Ma, H., Liu, H.-H., Li, S., Luo, X., Hu, R., Zhang, W., Lv, Z.-S., Niu, X.-L., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.008 · Cited by 15
Crab-shaped DNA tetrahedral nanomachine for silencing undruggable mRNA targets in prostate cancer
Wan, F., Liu, Z., Zhang, J., Zhang, W., & Dai, B. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102187 · Cited by 11
Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications
Zubirán, R., Cruz‐Bautista, I., & Aguilar-Salinas, C. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01626-2 · Cited by 11
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14
Yi, C., & Yu, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.893846 · Cited by 12
Evans, P. C., Davidson, S. M., Wojta, J., Bäck, M., Bollini, S., Brittan, M., Catapano, A. L., Chaudhry, B., Cluitmans, M. J. M., Gnecchi, M., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac114 · Cited by 12
Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure
Trudsø, L. C., Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4798 · Cited by 10
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 11
Cowart, K., Singleton, J., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.011 · Cited by 11
Next-generation therapeutics for rare genetic disorders
Sankar, A. A., Ravi Kumar, Y. S., Singh, A., Roy, R., Shukla, R., & Verma, B. (2024) · Mutagenesis · doi:10.1093/mutage/geae002 · Cited by 13
Zimoń, M., Huang, Y., Trasta, A., Liu, J., Liu, J. Z., Chen, C.-Y., Pepperkok, R., Klaus, B., Whelan, C. D., Sexton, D., et al. (2020) · Nature Communications · doi:10.1016/j.atherosclerosis.2020.10.593 · Cited by 10
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13
Xu, Y., Lu, J., Guo, Y., Zhang, Y., Liu, J., Huang, S., Zhang, Y., Gao, L., & Wang, X. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.05.009 · Cited by 13
Zyryanov, S. K., & Butranova, O. I. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5271 · Cited by 10
Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression
Zhang, C., Zhang, Y., Yu, Y., Zhou, M., Zhang, J., Fu, K., & Li, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177879 · Cited by 10
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 11
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 11
Snel, M., & Descamps, O. S. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2256182 · Cited by 10
Phospholipid biomarkers of coronary heart disease
Morita, S. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00344-y · Cited by 10
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 15
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia
Damase, T. R., Sukhovershin, R. A., Godin, B., Nasir, K., & Cooke, J. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067957 · Cited by 11
Ho, V. Q. T., Tran, N. B., Nguyen, N. M. T., Arrighini, G. S., Downes, D., Dandamudi, M., Ferrara, V. Z., Ho, T. H. Q., Walia, H., Barbagelata, A., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003490 · Cited by 11
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 14
Translating genetic association of lipid levels for biological and clinical application
Crone, B., Krause, A., Hornsby, W., Willer, C. J., & Surakka, I. L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07156-4 · Cited by 10
Inclisiran – a new era in lipid-lowering therapy
Voevoda, M. I., Gurevich, V. S., Владиславович, Е. М., & Сергиенко, И. В. (2022) · Kardiologiia · doi:10.18087/cardio.2022.6.n2115 · Cited by 10
Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11
Iluţ, S., Pîrlog, B. O., Pîrlog, R., Nutu, A. M., Văcăraș, V., & Armean, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810221 · Cited by 11
Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
Gabel, M., Knauss, A., Fischer, D., Neurath, M. F., & Weigmann, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213929 · Cited by 13
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Singh, A., & Cho, L. S. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23058 · Cited by 12
Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials
Olatunji, G. D., Kokori, E., Yusuf, I. A., Akinmoju, O. D., Egbunu, E. O., Muogbo, I., Lema, K. F., Kanagala, S. G., Owolabi, S., Muili, A. O., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102419 · Cited by 10
Carvalho, C., Williams, C., Raisi‐Estabragh, Z., Rison, S. C. G., Patel, R. S., Timmis, A., & Robson, J. P. (2021) · Heart · doi:10.1136/heartjnl-2020-318714 · Cited by 10
Insights from ORION studies: focus on inclisiran safety
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa139 · Cited by 10
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9
Self-citationGene and cell therapy approaches for familial hypercholesterolemia: An update.
Parsamanesh, N., Kooshkaki, O., Siami, H., Santos, R., Jamialahmadi, T., & Sahebkar, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103470 · Cited by 10
Metadata
- Authors
- Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., & Kastelein, J. J. P.
- Affiliations
- University of the Witwatersrand (ZA)
- Medpace (United States) (US)
- From the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.); the Medicines Company, Zurich, Switzerland (D.K.); the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London (K.K.R.); Medpace Reference Laboratories, Cincinnati (T.T.); Deutsches Herzzentrum München, Technische Universität München, and German Center for Cardiovascular Research, Munich Heart Alliance, Munich (W.K.), and the...
- Mayo Clinic (US)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1520-1530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3011005820
- Semantic Scholar
- cd7f15bcb062953bf710c34645a08f7b4818c4d9
- Cited by
- 818
- References
- 52
- Citations by year
- 2026: 88 · 2025: 126 · 2024: 142 · 2023: 154 · 2022: 140 · 2021: 111 · 2020: 56
- FWCI
- 105.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, heterozygous familial hypercholesterolemia, PCSK9 inhibition, siRNA, LDL cholesterol lowering, atherosclerotic cardiovascular disease prevention, hypercholesterolemia treatment, lipid-lowering therapy, PCSK9 monoclonal antibodies
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Treatment Outcome, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
